title: Perspective. The failure of cholesteryl ester transfer protein inhibitors: is it due to increased blood viscosity?
authors.affiliation: Department of Pathology, Benefis Hospitals, Great Falls, MT 59405, USA bigdaddypathologist@myway.com.
authors.forename: Gregory D
authors.initials: GD
authors.lastname: Sloop
authors.affiliation: Thomas Jefferson University, Philadelphia, PA, USA.
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Weidman
authors.affiliation: Jacqmar, Inc., Minneapolis, MN USA.
authors.forename: John A
authors.initials: JA
authors.lastname: St Cyr
mesh_terms: D000577:Amides; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001809:Blood Viscosity; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000401:mortality; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors*; D004903:Erythrocyte Aggregation / Q000187:drug effects; D004952:Esters; D006801:Humans; D011804:Quinolines / Q000627:therapeutic use; D013438:Sulfhydryl Compounds / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D000577:Amides; D000924:Anticholesteremic Agents; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D004952:Esters; D011804:Quinolines; D013438:Sulfhydryl Compounds; C411602:dalcetrapib; C483909:torcetrapib